<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / adolfosturdi / Upvoted</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Fri, 12 Aug 2022 14:57:01 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[PhytaZenica]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=phytazenica</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=phytazenica"><![CDATA[PhytaZenica]]></source>
	<description><![CDATA[In 2016 the FDA relaxed botanical drug approval guidelines to catch up with global standards, creating a huge opportunity for the worldwide expansion of botanical medicine. The global botanical medicine industry is an open and untapped $300 billion market. PhytaZenica ("fi-duh-zeh-ni-kuh") is a healthcare tech company that provides digital products and services to accelerate the development and approval of botanical medicine. ]]></description>
	<pubDate>Fri, 12 Aug 2022 14:57:01 +0000</pubDate>
	<author>adolfosturdi</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=phytazenica</guid>
</item>

</channel>
</rss>
